In addition, the differential sensitivity of distinct leukemia subtypes such as high risk AML or BCR-ABL positive leukemia to Aurora kinase inhibitors should be explored further to optimize the efficacy of this family of agents [41]–[43]. This evidence concerns the gene ABL1 and leukemia.